West Pharmaceutical (WST) Services announced the opening of its new building at its current site in Damastown, Dublin. The 165,000 square foot expansion significantly enhances West’s contract services and is designed to meet growing global demands of its customers’ high-volume treatments, including diabetes and obesity. The Damastown expansion enhances West’s contract capabilities beyond its component molding, device assembly, and packaging to now include advanced automation and expanded drug-handling capabilities at commercial scale.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- Orderly Leadership Transition and Reaffirmed 2026 Targets Underpin Buy Rating on West Pharmaceutical
- West Pharmaceutical says CEO Eric Green to retire
- Customer Concentration Risk: How Dependence on Key Accounts Threatens West Pharmaceutical’s Financial Stability
- West Pharmaceutical announces new $1B share repurchase program
- West Pharmaceutical price target lowered to $300 from $370 at BofA